Chimeric antigen receptor, macrophage expressing chimeric antigen receptor and application thereof
By expressing chimeric antigen receptor NKG2D CAR-M cells on macrophages, the infiltration and immunosuppression of CAR-T cells in solid tumor treatment were solved by using the NKG2D recognition area and CD3ζ signaling area, and the infiltration and immunosuppression of CAR-T cells in solid tumor treatment were achieved, and solid tumors were achieved The efficient killing and swallowing significantly improves the therapeutic effect.
Patent Information
- Application Number
- CN202210698985.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-20
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-06-20
AI Technical Summary
There are difficulties in treating solid tumors such as tumor heterogeneity, difficulty in infiltration of CAR-T into the tumor, and the impact of the immunosuppressive microenvironment of solid tumors, resulting in unsatisfactory treatment results.
Design a chimeric antigen receptor to be expressed on macrophages, using the NKG2D extracellular segment as the recognition region, and combining CD3ζ as the intracellular signal region to form NKG2D CAR-M cells, which can target NKG2D ligands and specifically kill and phagocytosis of tumor cells and improve the immune microenvironment in the tumor microenvironment.
NKG2D CAR-M cells can effectively kill and phagocytosis tumor cells, improve the tumor microenvironment, and enhance the therapeutic effect. They especially show superiority in the treatment of solid tumors. They have better infiltration ability and antigen presentation than CAR-T cells. Function.
Smart Images

Figure CN114989310B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of tumor treatment, specifically to cell immunotherapy for tumors, especially to NKG2DCAR-M cell immunotherapy, and more specifically to a chimeric antigen receptor, a macrophage expressing a chimeric antigen receptor, and applications thereof. Background Art
[0002] The global cancer statistics in 2018 show that in just one year, there were 18.1 million new patients and 9.6 million deaths worldwide, of which 3.804 million new cases and 296,000 deaths were reported in my country alone. Such a severe situation seriously threatens the health of our people and imposes a huge burden on the social economy. Although with the rapid development of medical technology, more and more methods are being used to treat tumors, it is far from enough. Therefore, the development and research of new methods for tumor treatment will remain a top priority for a long time to come.
[0003] Malignant tumors have always been a major disease that poses a serious threat to human health due to the inadequate efficacy of treatment and low cure rates. Traditional radiotherapy and chemotherapy aim to directly eliminate tumors, but tumors often recur and metastasize, and kill normal tissue cells. The purpose of cell immunotherapy for tumors is to promote or modify immune cells to attack cancer cells while maintaining the integrity of normal cells. Compared with traditional radiotherapy and chemotherapy, adoptive cell therapy has good specificity, safety, effectiveness and durability, and ranked first among the top ten scientific and technological advances in 2013.
[0004] In recent years, adoptive cell therapy based on DCs, T cells, NK cells, etc. has achieved good results in tumor treatment. In particular, immune cell therapy technology represented by chimeric antigen receptor T cells (CAR-T) has shown strong efficacy and huge development potential in the treatment of hematological tumors, and has become a new hope for human beings to fight cancer. Chimeric antigen receptor (CAR) T cell immunotherapy is a tumor adoptive cell immunotherapy. The basic principle is to use genetic engineering to modify T lymphocytes to express chimeric antigen receptors and kill tumor cells in a non-major histocompatibility complex (MHC) restricted manner. Although CART cells have achieved good results in clinical and clinical trials, they have also caused more serious side effects, including cytokine release syndrome, neurotoxicity and off-target effects. Moreover, CAR-T cell therapy has a very strong therapeutic effect on hematological malignancies, especially against acute lymphoblastic leukemia (ALL), but the effect of using CAR-T cells to treat solid tumors is not ideal. There are several reasons why CAR-T cell therapy has not made a major breakthrough in the treatment of solid tumors: First, CAR-T cells must be transported and infiltrated into tumors, a process that requires extravasation, chemotaxis, and matrix tissue penetration. CAR-T cells must pass through abnormal tumor blood vessels with reduced adhesion molecules, experience chemokine / chemokine receptor mismatch, and must migrate through dense cell and matrix barriers. After entering the tumor microenvironment (TME), effector cells encounter adverse conditions such as hypoxia and acidic environment, expression of immune checkpoint ligands, and a large number of immunosuppressive cells such as tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), and regulatory T cells (T-regs). In addition, long-term antigen exposure can lead to T cell exhaustion, thereby reducing the effector function of CAR T cells. Even if CAR-T cells survive in the TME, solid tumors often have heterogeneous surface antigen expression, which may lead to escape from CAR T cell detection, incomplete tumor clearance, and eventual growth of antigen-negative tumor cells. This has been clearly demonstrated in the treatment of glioblastoma using CAR T cells targeting EGFRvIII, where EGFRvIII expression was reduced in 5 / 7 patients after treatment.Finally, CAR-T cells may recognize tumor-associated antigens in normal tissues and cells, leading to on-target / off tumor toxicity, which is another obstacle to solid tumor cell therapy. Therefore, the development of new anti-tumor immune cell types may make up for the shortcomings of CAR-T in this regard, resist the immunosuppressive effects of the local tumor microenvironment of solid tumors, and thus achieve a synergistic anti-tumor effect.
[0005] NKG2D, as a member of the C-type lectin superfamily, is an important activating receptor in the innate immune system. + It is expressed on the surface of T cells, activated macrophages and tumor-infiltrating γδT cells. There are two main types of NKG2D ligands: one is MHC class I chain-related A / B molecules (MIC-A / B), and the other is UL16 binding protein 1-6 (ULBP1-6). NKG2D ligand (NKG2DL) is mainly expressed on most tumor cells, such as pancreatic cancer, ovarian cancer, prostate cancer, liver cancer, etc., and is almost not expressed on normal cells. NKG2D / NKG2DL plays a very important role in the immune regulation of tumors, and initiates the body's inherent immune surveillance and clearance in the early stage of tumor occurrence. NKG2D on immune cells transmits activation signals and activates the immune system by recognizing NKG2D ligands induced on the surface of tumor cells, thereby playing a killing role on tumor cells. However, the immune system in cancer patients is often weak, the number of immune cells in the body is small, and the ability to kill tumor cells is poor.
[0006] In recent years, the potential of macrophages to kill tumors has gradually attracted attention. Macrophages have a powerful phagocytic function, which recognizes tumor cells through cell surface receptors and then phagocytizes tumor cells. Although macrophages are also negatively affected by immunosuppressive factors in the tumor microenvironment, the research on these negative regulatory factors has been relatively sufficient, and there are corresponding means to control these factors. Therefore, by drawing on the concept of CAR-T targeted enhancement of the tumor killing function of effector T cells, it is worth exploring the possibility of using macrophages as cell carriers for immune cell therapy. Summary of the invention
[0007] In order to solve the obstacles in the prior art of CAR-T treatment of solid tumors, including tumor heterogeneity, difficulty for CAR-T to infiltrate into the tumor, and the influence of the immunosuppressive microenvironment of the solid tumor, the present invention aims to provide a chimeric antigen receptor, a macrophage expressing a chimeric antigen receptor, and an application thereof.
[0008] The technical solution of the present invention is as follows:
[0009] The first aspect of the present invention provides a chimeric antigen receptor, wherein the primary protein structure of the chimeric antigen receptor is, from the amino terminus to the carboxyl terminus, a signal peptide, an NKG2D extracellular region, a hinge region, a transmembrane region, and an intracellular signal region;
[0010] The NKG2D extracellular region is the extracellular domain of human NKG2D, and its amino acid sequence is shown in SEQ ID NO.2.
[0011] Further, the signal peptide is selected from CD8α signal peptide, CD28 signal peptide, CD4 signal peptide or GM-CSF signal peptide;
[0012] The hinge region is selected from the CD8α hinge region or the CD28 hinge region;
[0013] The transmembrane region is selected from the CD8α transmembrane region or the CD28 transmembrane region;
[0014] The intracellular signaling region is selected from CD3ζ or FcRγ.
[0015] Furthermore, the signal peptide is derived from human CD8α, and its amino acid sequence is shown in SEQ ID NO.1;
[0016] The hinge region is derived from human CD8α, and its amino acid sequence is shown in SEQ ID NO.3;
[0017] The transmembrane region is derived from human CD8α, and its amino acid sequence is shown in SEQ ID NO.4;
[0018] The intracellular signal region is CD3ζ, and its amino acid sequence is shown in SEQ ID NO.5.
[0019] The second aspect of the present invention provides a gene encoding the chimeric antigen receptor.
[0020] The third aspect of the present invention provides an expression vector containing the gene encoding the chimeric antigen receptor.
[0021] Furthermore, the expression vector is selected from a lentiviral expression vector, a retroviral expression vector or an adenoviral expression vector.
[0022] The fourth aspect of the present invention provides a macrophage expressing a chimeric antigen receptor, which comprises a gene encoding the chimeric antigen receptor or an expression vector of the gene encoding the chimeric antigen receptor.
[0023] Furthermore, the macrophages are derived from healthy humans or cancer patients;
[0024] The macrophages are selected from autologous macrophages, allogeneic macrophages or iPSC-induced macrophages;
[0025] Preferably, the macrophages are primary macrophages.
[0026] The fifth aspect of the present invention provides the use of the macrophage expressing chimeric antigen receptor in the preparation of tumor therapeutic drugs.
[0027] Further, the tumor is a tumor expressing NKG2D ligand;
[0028] The tumor is a blood tumor or a solid tumor;
[0029] Preferably, the tumor is leukemia, multiple myeloma, malignant lymphoma, glioma, liver cancer, lung cancer, gastric cancer, colon cancer, pancreatic cancer or breast cancer.
[0030] The beneficial effects of the present invention are:
[0031] 1. The present invention uses the natural sequence of the extracellular segment of NKG2D as the CAR recognition region, so that the chimeric antigen receptor has the advantages of low immunogenicity and easy expression, and can be normally expressed on macrophages, providing a basis for the preparation of chimeric antigen receptor macrophages (CAR-M) that specifically kill / phagocytize tumor cells. CD3ζ is preferably used as the intracellular signal region, and the ITAM structure contained in CD3ζ gives CAR-M a better phagocytic / tumor killing effect.
[0032] 2. The chimeric antigen receptor macrophage (CAR-M) of the present invention is a macrophage equipped with a CAR designed by the present invention, which can target NKG2D ligands, thereby specifically killing / phagocytizing tumor cells. The CAR-primary macrophages in the examples demonstrate the therapeutic effect of CAR-M. Compared with CAR-T, CAR-M has the advantages of: improving the tumor immune microenvironment of solid tumors; presenting antigens as antigen-presenting cells after phagocytizing tumor cells; more easily infiltrating into the tumor, cooperating with other immune cells to infiltrate the tumor, etc. Therefore, the CAR-M cells targeting NKG2D ligands of the present invention have important application value in the treatment of tumors (especially solid tumors). BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 : Schematic diagram of NKG2D chimeric antigen receptor (NKG2D CAR).
[0034] Figure 2 : CAR positivity rate of NKG2D CAR-M cells.
[0035] Figure 3 : The killing rate statistics of each group after 48 hours of killing (effector cells: target cells = 1). DETAILED DESCRIPTION
[0036] In order to understand the present invention more clearly, the present invention is further described with reference to the following examples and accompanying drawings. The examples are only used for explanation and are not intended to limit the present invention in any way. In the examples, each raw material reagent is commercially available, and the experimental methods without specifying specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.
[0037] Example 1
[0038] This embodiment provides a NKG2D chimeric antigen receptor (NKG2D CAR), and the primary protein structure of NKG2D CAR is sequentially from the amino terminus to the carboxyl terminus: signal peptide (Signal pep), NKG2D extracellular region (NKG2D ECD), hinge region (Hinge), transmembrane region (TM) and intracellular signal region. Among them, the signal peptide can be selected from the signal peptides of human CD8α, CD28, CD4, GM-CSF, etc.; the hinge region and transmembrane region can be selected from the hinge region and transmembrane region of human CD8α, CD28, etc.; the intracellular signal region can be selected from CD3ζ, FcRγ, etc.
[0039] In a specific embodiment ( Figure 1 ), the signal peptide is derived from human CD8α, and its amino acid sequence is shown in SEQ ID NO.1; the NKG2D extracellular region is the extracellular domain of human NKG2D (NM_007360.4), and its amino acid sequence is shown in SEQ ID NO.2; the hinge region and transmembrane region are derived from human CD8α, the amino acid sequence of the CD8α hinge region is shown in SEQ ID NO.3, and the amino acid sequence of the CD8α transmembrane region is shown in SEQ ID NO.4; the intracellular signal region is CD3ζ, which provides an activation signal, and its amino acid sequence is shown in SEQ ID NO.5. The specific nucleotide sequences: CD8α signal peptide (SEQ ID NO.6), NKG2D extracellular region (SEQ ID NO.7), CD8α hinge region (SEQ ID NO.8), CD8α transmembrane region (SEQ ID NO.9), CD3ζ intracellular signal region (SEQ ID NO.10) are artificially synthesized to obtain the NKG2D chimeric antigen receptor (NKG2D CAR) sequence.
[0040] The amino acid and nucleotide sequences in this example are as follows:
[0041] CD8α signal peptide amino acid sequence (SEQ ID NO.1):
[0042] MALPVTALLLPLALLLHAARP
[0043] NKG2D extracellular region amino acid sequence (SEQ ID NO.2):
[0044] IWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV
[0045] CD8α hinge region amino acid sequence (SEQ ID NO.3):
[0046] TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD
[0047] CD8α transmembrane region amino acid sequence (SEQ ID NO.4):
[0048] IYIWAPLAGTCGVLLLSLVITLYC
[0049] The amino acid sequence of CD3ζ intracellular signal region (SEQ ID NO.5):
[0050] RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
[0051] CD8α signal peptide nucleotide sequence (SEQ ID NO.6):
[0052] ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCG
[0053] NKG2D extracellular region nucleotide sequence (SEQ ID NO.7):
[0054] ATATGGAGTGCTGTATTCCTAAACTCATTATTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACTGTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAGTAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATACAGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAATAATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAACTGTTCAACTCCAAATACGTACATCTGCATGCAAAGGACTGTG
[0055] CD8α hinge region nucleotide sequence (SEQ ID NO.8):
[0056] ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT
[0057] CD8α transmembrane region nucleotide sequence (SEQ ID NO.9):
[0058] ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC
[0059] CD3ζ intracellular signaling region nucleotide sequence (SEQ ID NO.10):
[0060] AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAA GGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC
[0061] Example 2
[0062] (I) This example provides the preparation of NKG2D CAR-M cells, and the specific steps are as follows:
[0063] 1. NKG2D CAR adenovirus construction
[0064] NKG2D CAR adenovirus was packaged using the pAdEasy system recombinant adenovirus packaging system, and the backbone vector used for Ad5F35 adenovirus packaging was Ad5F35 Helper. Ad5F35-related packaging plasmids were transfected into HEK 293 cells using PEI, and the cells were cultured in a CO2 incubator after mixing. After 14 days of culture, the cells were collected by centrifugation at 3500g, and the precipitate was resuspended after adding adenovirus freezing solution. The suspension was repeatedly frozen and thawed four times at -80℃ and 37℃. After the freeze-thaw was completed, it was centrifuged at 12000g for 2min and the supernatant was collected. The collected viral supernatant was evenly added to 10 10cm culture dishes, mixed and cultured in a CO2 incubator. After 2-3 days, the supernatant and cells were collected by centrifugation. PEG8000 and NaCl were added to the viral supernatant, mixed and placed upright at 4°C overnight, and the supernatant was collected by centrifugation the next day; the cell pellet was stored at -80°C, and then adenovirus freezing solution was added and resuspended, and then repeatedly frozen and thawed 4 times, and the supernatant was collected after high-speed centrifugation. The remaining cells were ultrasonically broken, and the sample supernatant was collected after centrifugation. After all the collected samples were mixed, the virus was purified by iodixanol density gradient centrifugation, and finally the purified virus solution was filtered through a 0.22 micron filter membrane and packaged for low-temperature storage.
[0065] 2. Isolation of human peripheral blood mononuclear cells (PBMC) from whole blood
[0066] Add 25 mL of whole blood to a 50 mL centrifuge tube, and then add 25 mL of PBS to mix; add 15 mL of FICOLL reagent to the 50 mL centrifuge tube, and then slowly add 30 mL of the diluted whole blood along the wall; centrifuge at 20°C, 2110 r / min, rise 2 and fall 2, centrifuge for 30 minutes; after centrifugation, the liquid is divided into four layers, the top yellow liquid is removed, the second white film layer is aspirated in a circle, and the obtained white film layer liquid is divided into two tubes, PBS is added to 40-45 mL to mix, centrifuge at 20°C, 1800 r / min, rise 9 and fall 9, centrifuge for 8 minutes; remove the supernatant, add 40 mL of PBS to resuspend the two tubes into one tube, centrifuge at 20°C, 1200 r / min, rise 9 and fall 9, centrifuge for 8 minutes; remove the supernatant, add 40 mL of PBS to resuspend and count the remaining cells at 20°C, 1200 r / min, rise 9 and fall 9, centrifuge for 8 minutes; remove the supernatant, freeze with freezing solution for later use.
[0067] 3. Isolation of Human CD14 + cell
[0068] The revived PBMC cells were centrifuged at 300 g for 5 min and the supernatant was discarded. About 4-5 mL of MojoSort TM Resuspend in buffer. Filter the cells with a 70 μM cell sieve, centrifuge at 300 g for 5 min, remove the supernatant, and then use an appropriate volume of MojoSort TM Resuspend in Buffer and adjust the cell concentration to 1×10 8 / mL. Add 100μL of cell suspension (10 7 5 μL Human TruStain FcX TM (Fc receptor blocking solution), mix well and incubate at room temperature for 10-15 minutes. If more cells are separated, the amount of reagents will be increased in proportion. Add 10-20μL Biotin-AntibodyCocktail, mix well and incubate on ice for 15 minutes. If more cells are separated, the amount of reagents will be increased in proportion. Add 10-15μL Streptavidin Nanobeads resuspended by vortexing at maximum speed, mix well and incubate on ice for 15 minutes. If more cells are separated, the amount of reagents will be increased in proportion. Add 4mL of MojoSort TM Buffer was used to wash the cells, centrifuged at 300 g for 5-10 min, and the supernatant was discarded. Add 2.5-5 mL of MojoSort TM Resuspend the cells in a clean flow cytometry tube and place it on a magnetic stand for 5 minutes. Pour off and collect the liquid in a new 15mL centrifuge tube for later use. Then use 2.5mL MojoSort TMResuspend the remaining precipitate in buffer. Combine the collected liquids, centrifuge at 300g for 5 minutes, and then resuspend and count the cells in the prepared human primary macrophage culture medium (RPMI-1640 culture medium with 10% FBS, 1% PS, and human GM-CSF at a final concentration of 10-50ng / mL), and inoculate them in a non-TC treated 6-well plate for culture. A small portion of the cells can be taken for flow staining to detect their purity.
[0069] 4. Cultivation of Primary Human Macrophages
[0070] Use the prepared human primary macrophage culture medium to culture the isolated human CD14 + Cells were plated in non-TC treated 6-well plates (3-10×10 5 / mL), cultured in a 37°C, 5% carbon dioxide incubator. On the third day, half of the supernatant was gently aspirated and the medium was replaced. On the fifth day, the adherent cells obtained after the full medium replacement were human primary macrophages.
[0071] 5. Adenovirus infection of primary human macrophages
[0072] Isolated human CD14 + After the cells were counted, they were cultured in 6-well plates without TC treatment (3-8×10 5 / mL); after 5 days, adenovirus (control virus and NKG2D CAR adenovirus) was added at a virus titer of MOI = 200-1000; after 24-48h, the medium was replaced with virus-free medium; after 48-60h, the positive rate of CAR-M was detected: the digested CAR-M was subjected to flow staining to detect the expression of CAR.
[0073] Flow results show (attached Figure 2 ): The positive rate of NKG2D CAR-M is >50%, indicating that human primary CAR-M cells targeting NKG2D were successfully prepared.
[0074] (II) Detecting the killing effect of primary human CAR-M on tumor cells by the following methods
[0075] The fluorescence intensity was collected and analyzed using a SPECTROstar Omega microplate reader for cell killing experiments. First, NKG2D CAR-M, empty M (infected with adenovirus) and UTD-M (untreated with virus) cells were cultured at 2-5×10 4 / well inoculated into a light-proof 96-well cell culture plate, 5-10 duplicate wells per group, and left to stand for 24-48 hours. After 24 hours, PC-3 cells stably expressing luciferase (serum-free, M-CSF-free DMEM medium) were added at a ratio of effector cells: target cells = 1:1, and co-cultured with BMDM in each group. The experiment was divided into 4 groups: BLANK group; UTD-M group (no virus infection); empty M cell group (addition of adenovirus control group) and NKG2D CAR-M group (addition of NKG2D CAR adenovirus group).
[0076] After culturing in a 5% carbon dioxide incubator at 37°C for 24-48 hours, D-luciferin, potassium salt substrate at a concentration of 100-200 μg / mL was added to a light-proof 96-well plate. After incubation at 37°C in the dark for 10 minutes, the fluorescence intensity was collected and analyzed using a SPECTROstar Omega microplate reader, and the lysis of PC-3 target cells by NKG2D CAR-M was calculated using the following formula:
[0077] % cell lysis (Lysis%) = [1-(fluorescence signal of co-cultured cells-background fluorescence signal) /
[0078] (fluorescence signal of PC-3 cells cultured alone - background fluorescence signal)] *100
[0079] The killing results of PC-3 cells are shown in the attached Figure 3 As shown: The killing effects of UTD-M group and empty group cells on tumor cells were relatively weak, while the killing effect of NKG2D CAR-M group on tumor cells was significantly enhanced, proving the targeted killing function of NKG2D CAR-T.
[0080] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, obvious changes or modifications derived therefrom are still within the protection scope of the present invention. SEQUENCE LISTING <110> Shenzhen Institutes of Advanced Technology <120> Chimeric antigen receptor, macrophage expressing chimeric antigen receptor and application thereof <130> CP122010528C <160> 10 <170> PatentIn version 3.3 <210> 1 <211> twenty one <212> PRT <213> artificial sequence <400> 1 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro 20 <210> 2 <211> 144 <212> PRT <213> artificial sequence <400> 2 Ile Trp Ser Ala Val Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln 1 5 10 15 Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile 20 25 30 Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp 35 40 45 Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys 50 55 60 Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr 65 70 75 80 His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp 85 90 95 Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met 100 105 110 Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile 115 120 125 Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val 130 135 140 <210> 3 <211> 45 <212> PRT <213> Artificial Sequence <400> 3 Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala 1 5 10 15 Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 20 25 30 Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 35 40 45 <210> 4 <211> 24 <212> PRT <213> Artificial Sequence <400> 4 Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 1 5 10 15 Ser Leu Val Ile Thr Leu Tyr Cys 20 <210> 5 <211> 112 <212> PRT <213> Artificial Sequence <400> 5 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 6 <211> 63 <212> DNA <213> Artificial sequence <400> 6 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccg 63 <210> 7 <211> 432 <212> DNA <213> Artificial sequence <400> 7 atatggagtg ctgtattcct aaactcatta ttcaaccaag aagttcaaat tcccttgacc 60 gaaagttact gtggcccatg tcctaaaaac tggatatgtt acaaaaataa ctgctaccaa 120 ttttttgatg agagtaaaa ctggtatgag agccaggctt cttgtatgtc tcaaaatgcc 180 agccttctga aagtatacag caaagaggac caggatttac ttaaactggt gaagtcatat 240 cattggatgg gactagtaca cattccaaca aatggatctt ggcagtggga agatggctcc 300 attctctcac ccaacctact aacaataatt gaaatgcaga agggagactg tgcactctat 360 gcctcgagct ttaaaggcta tatagaaaac tgttcaactc caaatacgta catctgcatg 420 caaaggactg tg 432 <210> 8 <211> 135 <212> DNA <213> artificial sequence <400> 8 accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 60 tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg 120 gacttcgcct gtgat 135 <210> 9 <211> 72 <212> DNA <213> artificial sequence <400> 9 atctacatct gggcgccctt ggccgggact tgtggggtcc ttctcctgtc actggttatc 60 atctacatct gggcgccctt ggccgggact tgtggggtcc ttctcctgtc actggttatc 60 accctttact gc 72 accctttact gc 72 <210> 10<210> 10 <211> 336<211> 336 <212> DNA<212> DNA <213> Artificial sequence<213> Artificial sequence <400> 10<400> 10 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 tacgacgccc ttcacatgca ggccctgccc cctcgc 336
Claims
1. A macrophage expressing a chimeric antigen receptor, It is characterized in that The primary protein structure of the chimeric antigen receptor is sequentially composed of: a signal peptide, an NKG2D extracellular region, a hinge region, a transmembrane region and an intracellular signal region from the amino terminus to the carboxyl terminus; The NKG2D extracellular region is the extracellular domain of human NKG2D, and its amino acid sequence is shown in SEQ ID NO.2; The signal peptide is derived from human CD8α, and its amino acid sequence is shown in SEQ ID NO.1; The hinge region is derived from human CD8α, and its amino acid sequence is shown in SEQ ID NO.3; The transmembrane region is derived from human CD8α, and its amino acid sequence is shown in SEQ ID NO.4; The intracellular signal region is CD3ζ, and its amino acid sequence is shown in SEQ ID NO.5; The macrophages are primary macrophages.
2. The macrophage expressing a chimeric antigen receptor according to claim 1, It is characterized in that The macrophages are derived from healthy humans or cancer patients; The macrophages are selected from autologous macrophages or allogeneic macrophages.
3. Use of the macrophage expressing chimeric antigen receptor according to claim 1 in the preparation of a drug for treating solid tumors expressing NKG2D ligand.
4. The use according to claim 3, It is characterized in that The solid tumor is multiple myeloma, malignant lymphoma, glioma, liver cancer, lung cancer, stomach cancer, colon cancer, pancreatic cancer or breast cancer.
